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Establishing a wide therapeutic index (TI) for pre-clinical safety is important during lead
optimization (LO) in research, prior to clinical development, although is often limited
by a molecules physiochemical characteristics. Recent advances in the application
of the innovative vibrating mesh spray-drying technology to prepare amorphous solid
dispersions may offer an opportunity to achieve high plasma concentrations of poorly
soluble NCEs to enable testing and establishment of a wide TI in safety pharmacology
studies. While some of the amorphous solid dispersion carriers are generally recognized
as safe for clinical use, whether they are sufficiently benign to enable in vivo pharmacology
studies has not been sufficiently demonstrated. Thus, the physical properties, and effect
in a battery of in vivo safety pharmacology models, were assessed in three classes
of polymers employed as spray-dried dispersion carriers. The polymers (HPMC-AS,
Eudragit, PVAP) displayed low affinity with acetone/methanol, suitable for solvent-based
spray drying. The water sorption of the polymers was moderate, and the degree of
hysteresis of HPMC-ASwas smaller than Eudragit and PVAP indicating the intermolecular
interaction of water-cellulose molecules is weaker than water-acrylate or water-polyvinyl
molecules. The polymer particles were well-suspended without aggregation with a mean
particle size less than 3µm in an aqueous vehicle. When tested in conscious Wistar Han
rats in safety pharmacologymodels (n= 6–8/dose/polymer) investigating effects on CNS,
gastrointestinal, and cardiovascular function, no liabilities were identified at any dose
tested (30–300 mg/kg PO, suspension). In brief, the polymers had no effect in a modified
Irwin test that included observational and evoked endpoints related to stereotypies,
excitation, sedation, pain/anesthesia, autonomic balance, reflexes, and others. No effect
of the polymers on gastric emptying or intestinal transit was observed when measured
using a barium sulfate tracer material. Finally, in telemetry-instrumented rats the polymers
had no effect on acute or 24-h mean blood pressure and heart rate values at doses up to
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300mg/kg. Thus, the properties of the three enteric polymers are appropriate as
spray-dried dispersion carriers and were benign in a battery of safety pharmacology
studies, demonstrating their applicability to enable in vivo safety pharmacology profiling
of poorly soluble molecules during LO.
Keywords: amorphous solid dispersion, spray-dried dispersion, safety pharmacology, drug discovery
INTRODUCTION
Safety pharmacology studies in drug discovery are often
performed during compound selection in lead optimization,
prior to entry into long-term dose-escalation studies (Hamdam
et al., 2013). Moreover, to protect the Phase I volunteer, in vivo
studies are mandated by regulatory authorities in key organ
systems, including testing in models to investigate effects on
CNS, respiratory, and cardiovascular function (USDHHS, 2001).
Effects on other organ systems (e.g., gastrointestinal and renal
function) are also commonly assessed as part of a comprehensive
battery of in vivo safety profiling (Al-Saffar et al., 2015; Benjamin
et al., 2015).
While establishing a wide therapeutic index (TI) in these
models is important prior to advancement of new chemical
entities (NCEs) into clinical development, molecules are often
encountered with poor aqueous solubility and dissolution
characteristics, and consequently, a poor pharmacokinetic profile
that limits the ability to achieve high plasma levels after oral
administration. Thus, to establish a wide TI for poorly soluble
molecules the use of enabling formulations is essential (Li and
Zhao, 2007) and whereby the formulation does not interfere
with the primary safety endpoints being measured. While some
excipients are recognized as safe for clinical use, animal species
may respond differently as recently discussed by Turner et al.
(2011) who note that some excipients believed to be safe in man,
non-human primates, and dogs are not well tolerated in rodents,
and vice versa. Moreover, excipient tolerance can be impacted by
the fasted/fed state of the animal who may become less tolerant
of excipients as their plane of nutrition decreases (Li and Zhao,
2007).
While an enteric polymer, such as those tested in the present
study, would not be absorbed into the blood, it is well established
that within the digestive system, GI reflexes can be modulated
through both systemic as well as complex local and regional
effects processed entirely within the digestive system itself (e.g.,
to control secretion and local motility via gastro-colic, entero-
gastric, and colono-ilial reflexes) ultimately affecting GI function
(Furness et al., 2014; Al-Saffar et al., 2015). The importance
of proper formulation excipient characterization has also been
noted specifically in support of small-animal telemetry profiling
for cardiovascular safety (Guth, 2007) to enable detection
of the low-magnitude yet physiologically-relevant effects, and
where volume, dose rate, and physicochemical characteristics
of the excipient are critical factors impacting hemodynamic
responses (Authier et al., 2015). The same principles apply to
CNS functional assessments where prior formulation evaluation
is essential when comparing subjective scores as commonly
employed in a Functional Observational Battery or Irwin profile
(Fonck et al., 2015).
Thus, a proper balance between selecting a formulation
to achieve high drug levels vs. biocompatibility and in vivo
tolerability must be developed to minimizing confounding
effects of the formulation excipients (Li and Zhao, 2007). The
latter is highlighted in the observation that some enabling
solution formulations are not suitable for in vivo evaluation
due to the adverse effect profile of vehicles composed of
organic solvents, surfactants, lipids, or complexing agents (Pestel
et al., 2006). The amorphous solid dispersion approach is
considered one of the most promising strategies to address
bioavailability issues that are mediated by solubility and
dissolution-limited absorption (Vasconcelos et al., 2007; Padden
et al., 2010; Newman et al., 2012). In an amorphous solid
dispersion system, the carrier plays a critical role because the
carrier is a determinant of physical stability, dissolution, and
supersaturation of the amorphous drug. The development of
amorphous solid dispersions using pre-selected carriers that can
enhance plasma exposure and are also suitable for in vivo use
is of significant value in pharmacology studies where testing at
pharmacologic or supratherapeutic doses is limited by less-than-
ideal physiochemical characteristics of the molecule. Moreover,
added value is evident for those pharmacology sub-specialties
whereby administration at large, often supratherapeutic, doses
is necessary to achieve a wide TI as dictated in pre-clinical
safety pharmacology studies and longer-term toxicological
profiling.
While amorphous solid dispersions have been increasingly
used to enhance bioavailability of poorly soluble molecules at
later stages of the drug development process, this approach has
had limited utility during lead optimization. This is primarily
because preparing reliable amorphous solid dispersions at the
milligram scale is technically challenging, requiring considerable
development time and drug substance. However, in previous
studies we have demonstrated that utilization of the B-90 spray
drier (B-90) using vibrating mesh technology is an effective way
to prepare amorphous spray-dried dispersions in the discovery
research stages (Gu et al., 2015; Tseng, 2015).
In the present study, we evaluated three enteric polymers
from three distinct classes and with different structures that are
commonly used as amorphous solid dispersion carriers including
cellulose-based hydroxypropylmethylcellulose acetate succinate-
LF (HPMC-AS), acrylate-based EUDRAGIT L100-55 (Eudragit),
and polyvinyl-based polyvinyl acetate phthalate (PVAP). These
enteric polymers were selected for this studies because they
dissolve at pH > 5.5 and are not soluble in acidic gastric
fluid and water which can prevent the pre-mature release of
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the incorporated drug molecule during the preparation before
dosing.
Although these polymers are generally recognized as safe
for clinical use, to the best of our knowledge very few studies
have been performed to demonstrate that these polymers are
sufficiently benign in pre-clinical models to enable in vivo safety
pharmacology studies where small changes in organ function and
physiology are assessed during lead optimization. The current
studies focused on the comparison of the basic physicochemical
properties of these three enteric polymers as spray-dried
dispersion carriers and their tolerability in safety pharmacology
models investigating effects on CNS, gastrointestinal, and
cardiovascular function.
MATERIALS AND METHODS
Materials
HPMC-AS was purchased from Shin-Etsu Chemical Co. Ltd.
(Tokyo, Japan). EUDRAGIT L 100-55 and PVAP were provided
by Degussa GmbH (Linden, NJ) and by Colrcon, Inc. (West
Point, PA), respectively. All other chemical reagents used in this
study were of ACS-grade purity.
Preparation of Spray-Dried Powders
Spray-dried powders were prepared by means of spray drying
using B-90 (BÜCHI Labortechnik AG, Flawil, Switzerland).
HPMC-AS was dissolved in acetone, Eudragit in a mixture of
acetone and methanol (8/2), and PVAP in acetone and methanol
(9/1) to produce 1% (w/v) solution solutions for spray drying.
After centrifuging each solution at 3000 rpm for 15min, the
supernatants were spray dried. For the spray-drying process, the
pump speed, air flow rate, and inlet temperature were set at
2, 120 L/min, and 75◦C, respectively, and a 7-mm mesh nozzle
cap was used. Dried powders were collected, and the collected
powders were further dried in a vacuum oven at 40◦C for 3 days.
Thermogravimetric Analysis (TGA)
The prepared spray-dried powders were analyzed using a TGA
Q500 from TA instruments (New Castle, DE) to determine the
moisture and volatile contents. The samples were heated at
10◦C/min from 25 to 200◦C in an inert environment maintained
by dry N2 purge at 100mL/min. The percentage weight loss
integrated up to 110◦C was accounted for the moisture and
solvent loss. Data analysis utilized Universal Analysis 2000
thermal analysis software by TA Instruments.
Dynamic Vapor Sorption (DVS)
Dynamic gravimetric vapor sorption of spray-dried polymers was
done by DVS (Surface measurement systems, Allentown, PA)
using water as the solvent. Approximately 5–20mg of sample was
placed into the instrument microbalance where it was dried at
25◦C until constant weight was recorded. The dried sample was
then exposed to differing humidity’s up to 90% RH at 25◦C. Mass
change was recorded at different humidity’s. The equilibrium
criterion was 0.0015% mass change. The Adsorption/desorption
isotherm curve was plotted using the DVS software.
Light Microscopy and Particle Size
Measurement
Spray-dried powders were suspended in an aqueous solution
of 0.5% methylcellulose (MC) and 0.015% Tween 80, or in
the McIlvaine buffer at pH6. The suspension or solution was
sandwiched between a glass slide and a coverslip and visualized
under a light microscope of Nikon Eclipse Ti (Nikon, Tokyo,
Japan). Microscope images were taken in the PLM mode from
an attached Nikon DS-Ri2 digital camera (Nikon, Tokyo, Japan).
Particle size measurements were performed on the captured
images using NIS-Element Imaging software. Average particle
size was expressed as the area mean diameter, and D50 and D90
are the particle diameters determined respectively at the 50th and
90th percentiles of undersized particles.
In vivo Safety Pharmacology Studies
All in vivo experiments and procedures were performed under
protocols approved by the Boehringer Ingelheim Institutional
Animal Care and Use Committee. Procedures involving animals
and their care were either conducted in conformity with
the United States Animal Welfare Act or the European
Union guidelines (EEC Council Directive 86/609). The in vivo
experiments performed in Germany (gastrointestinal function)
were approved by the Ethical Committee of the responsible
regional council (Tübingen).
The three spray-dried polymers (HPMC-AS, Eudragit and
PVAP) were tested in suspension at 30, 100, and 300 mg/kg
p.o. (10 mL/kg) in conscious male Wistar Han rats (Charles
River, Kingston NY, US; or Sulzfeld, Germany). CNS functional
studies were performed at n = 6/dose of each polymer.
GI functional studies were performed at n = 7–8/dose of
each polymer. Cardiovascular studies were performed at n =
8/dose of each polymer. Results were compared to a 0.5%
methylcellulose/0.015% Tween 80 control vehicle in dH2O and
detailed statistical methods are provided below.
CNS Function
The systematic observation of animal behavior and psychological
state, originally described by Irwin (1968) is a widely used
method to determine the side effect liability potential of
novel agents on CNS function. In a modified Irwin study
(n = 6/dose) that assessed effects on CNS function at 1,
2, and 4 h post-treatment, rats (weight range = 165–275 g)
were placed in observation cylinders for evaluation followed
by brief handling and manipulation testing. The number of
animals used in the study is based on prior experience with
the model where n = 6 has been sufficient to demonstrate
effects of positive control agents including d-amphetamine,
diazepam, and others (results not shown). The modified Irwin
study assessed six broad categories of CNS function including
stereotypy, excitation, sedation, pain/anesthesia, autonomic
balance, reflexes, and other non-categorized effects; specific
parameters that were assessed included motor activity, ataxia,
paralysis, tremor, convulsions, respiration, salivation, skin color,
feces, death, righting reflex, visual orientation, grip reflex,
muscle tone, body temperature, and tail pinch. Effects, when
noted, were qualitatively characterized as a mild, moderate, or
Frontiers in Pharmacology | www.frontiersin.org 3 October 2016 | Volume 7 | Article 368
Fryer et al. Drug Dispersions in Safety Pharmacology
marked response. Relative to vehicle controls an observation was
considered “infrequent” if a response was observed in 50% or
fewer animals and was deemed mild in magnitude. An effect was
described as “limited observations” if observed in 50% or fewer
animals at a mild or moderate magnitude. An observation was
considered “frequently observed” of observed in greater than half
of the animals of any magnitude (mild, moderate, or marked
severity). Results were summarized for each vehicle across the six
broad categories in Table 2.
GI Function
Indices of gastrointestinal (GI) function (gastric emptying and
GI transit) were assessed at 2-h post-dose (n = 7–8/dose). The
number of animals used in the study is based on prior experience
with the model testing including the evaluation of positive
control agents including codeine, carbachol, and others (results
not shown). Thirty minutes prior to assessment rats (7 weeks
of age, 130–160 g) were administered a barium sulfate test meal
suspension, an opaque substance easily visualized in the GI tract;
barium sulfate was formulated as 10 g BaSO4 in 10mL salt-free
water and administered at 20mL/kg body weight by oral gavage.
At 2-h post-dose, and after 30-min of barium sulfate transit
time, rats were euthanized and the intestine/stomach removed
(stomach to cecum). The extent of barium sulfate GI transit
was expressed as a percent of the total intestine length. Gastric
emptying was reported as the difference in full and empty dry
weight of the stomach. The percent effect on both transit and
gastric emptying was calculated relative to vehicle (mean± SD).
Hemodynamics
Male Wistar Han rats (n = 8/dose) were instrumented with
telemetry transmitters (DSI, St. Paul, MN) as previously
described (Fryer et al., 2012a) to continuously record
hemodynamic parameters while conscious and freely moving
after oral administration. Group size was based on prior
experience with the model and as previously described (Fryer
et al., 2012b). All animals (28–30 weeks of age, 357–521 g) were
single housed and acclimated to metabolic cages for 3 days.
Blood pressure, heart rate and bodyweight were collected during
a 24-h baseline period and animals were randomized. Effects
on mean arterial blood pressure and heart rate were assessed
reported as 10 min mean values for 24 h of baseline and 24-h
post-administration.
Statistical Analysis
Statistical analyses were performed for studies investigating
effects on GI and cardiovascular function; since only
observational endpoints were assessed in the modified Irwin
profile no statistical analysis was performed for those studies.
In GI functional studies statistical significance was determined
separately for gastric emptying and GI transit endpoints and
separately for each polymer. For each polymer, values were
assessed at all doses tested using a one-way ANOVA and
Dunnett’s multiple comparison to the vehicle control group;
p < 0.05 was considered statistically significant (GraphPad
Prism 6.0). In studies performed in telemetry rats investigating
effects on hemodynamics, two separate statistical analyses were
performed. Baseline values (mean arterial blood pressure and
heart rate) were defined as the average of all values collected
during the 24-h period prior to treatment; values were compared
using a one-way ANOVA and Dunnett’s multiple comparison to
the vehicle control group; p < 0.05 was considered statistically
significant (GraphPad Prism 6.0). For analysis of individual
timepoints during the 48-h period, a two-way ANOVA with
Dunnett’s multiple comparison test vs. the Control Vehicle
group (GraphPad Prism 6.0, p < 0.05) was performed based on
change from baseline in the hemodynamic values; statistically
significant values are denoted within the figures using asterisks
in the corresponding group color.
RESULTS AND DISCUSSION
The structures, average molecular weight, and pH-solubility
threshold of the three selected polymers are shown in Figure 1.
They are ionic polymers, and their pH-solubility thresholds are
5.5, 5.5, and 5.0 for HPMC-AS, Eudragit, and PVAP, respectively.
This means that the polymers are not soluble in acidic gastric
fluid, but swell and dissolve rapidly at a pH > 5.5. All three
polymers as reported in the literature have good solubility in
acetone, methanol, or their combination (Rowe et al., 2006;
Sullivan, 2008; Evonik Nutrition and Care Gmb, 2015). A key
prerequisite for preparing amorphous solid dispersions with the
solvent-based spray drying technology is to dissolve a compound
and a polymer carrier in a common volatile solvent (typically
acetone or methanol), followed by spray-drying. During the
spray-drying process, the solvent rapidly evaporates from the
droplets to rapidly solidify the polymer and drug mixture,
trapping the drug as an amorphous molecular dispersion, but
the solvents may also get entrapped in the spray-dried powders
(Sollohub and Cal, 2010). In addition to safety concerns, the
residual solvent, even at low levels, can cause recrystallization
of the amorphous compound in solid dispersions, potentially
having a detrimental effect on the stability of the dispersed
amorphous compound (Andronis et al., 1997). Therefore, it is
important that the amorphous solid dispersion carriers have
a minimal affinity with the solvents. The amount of solvent
trapped in the spray-dried powders was assessed with TGA
for a total volatile content. As shown in Figure 2, there was
no entrapped acetone in HPMC-AS, and a very small amount
of acetone/methanol was entrapped in Eudragit and PVAP,
suggesting a low affinity between the three polymers and the
solvents, and HPMC-AS has the lowest affinity.
Hygroscopicity of amorphous solid dispersion carriers is
recognized as a critical factor in determining the physical
stability or crystallization tendency of amorphous compounds,
because absorbed water can cause recrystallization of dispersed
amorphous compounds. A water vapor sorption isotherm
provides information about the affinity between amorphous solid
dispersion carriers and water. Figures 3A–C exhibit water vapor
sorption and desorption isotherms for HPMC-AS, Eudragit,
and PVAP, respectively, and Figure 3D displays hysteresis over
the humidity range of 0–90% RH. As shown in Figures 3A–C,
these three amorphous polymers, like any other amorphous
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FIGURE 1 | Structure, MW, and pH-solubility threshold of Hydroxypropylmethylcellulose acetate succinate (HPMC-AS) (A), Methacrylic Acid-Ethyl
Acrylate Copolymer (1:1) (Eudragit® L 100-55) (B), and Polyvinyl acetate phthalate (PVAP) (C).
FIGURE 2 | Thermogravimetric analysis (TGA) of spray-dried HPMC-AS, Eudragit, and PVAP. The percentage weight loss integrated up to 110◦C is
accounted for the moisture and solvent loss.
materials, absorbed water when exposed to humid air. The degree
and pattern of water uptake was practically the same for all
polymers. The water uptake was slow and continuous through
the entire range of humidity, and the observed changes in mass
were 10.5, 10.0, and 10.4% for HPMC-AS, Eudragit, and PVAP,
respectively, at 90% RH. Other researchers reported that enteric
polymers are less hygroscopic than water-soluble polymers such
as povidone or copovidone, thereby imparting better stability to
the amorphous form (Marsac et al., 2008; Rumondor et al., 2009).
The displayed water vapor sorption isotherm is the total sorption
contributed by both surface adsorption and bulk absorption
(Crowley and Zografi, 2002). The moisture taken by the bulk
absorption into the structure of amorphous solid dispersions
may induce phase separation of the drug-polymer system and
subsequent crystallization of amorphous drugs (Konno and
Taylor, 2008; Marsac et al., 2010). As shown in Figures 3A–C,
all three polymers had certain degree of hysteresis between the
sorption and desorption isotherm, which is mainly induced
by the bulk absorption, and water is absorbed more quickly
than being released (Crowley and Zografi, 2002). The degree
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FIGURE 3 | Sorption and desorption isotherms for spray-dried HPMC-AS (A), Eudragit (B), PVAP (C), and isotherm hysteresis (D) of spray-dried
HPMC-AS (•), Eudragit (N), and PVAP ().
of hysteresis for HPMC-AS is smaller than that of Eugragit
and PVAP (Figure 3D), indicating the intermolecular interaction
of water-cellulose molecules is weaker than the Eudragit and
PVAP. Chokshi et al. (2008) have shown that polymers with
ionic groups, such as HPMC-AS, Eudragit or PVAP etc., can
help stabilize amorphous systems by not only providing an
opportunity for ionic interactions but also by providing low
water activity as they are insoluble in water. Rumondor et al.
(Rumondor and Taylor, 2010) has also reported that the extent
of water sorption depends on the hygroscopicity of both polymer
and drug (McConnell et al., 2008). Thus, an amorphous solid
dispersion system with a lower hygroscopicity may lead to a
greater resistance against moisture-induced phase separation,
and the HPMC-AS system containing the least bulk absorption
is least susceptible to phase separation.
One of the biggest challenges to dose amorphous solid
dispersions in early pre-clinical studies, especially for rodents,
is that amorphous solid dispersions need to be suspended in
aqueous dosing vehicles during the dosing preparation period
TABLE 1 | Particle size of spray-dried powders of HPMC-AS, Eudragit, and
PVAP dispersed in the aqueous vehicle (0.5% MC and 0.015% Tween); n =
3, 1000–20,000 particles per sample.
Particle size (µm)
Mean Range D50 D90
HPMC-AS 2.7 ± 2.9 0.15–19 2.0 5.0
Eudragit 0.8 ± 3.8 0.5–11 0.8 2.0
PVAP 0.5 ± 2.3 0.2–4 0.4 0.9
before dosing. Therefore, it is critical that the amorphous
solid dispersion carriers can be homogeneously suspended in
the aqueous dosing vehicle without dissolving to prevent pre-
maturely releasing the drug and to avoid crystallization of
incorporated amorphous compounds at least 2–4 h for dosing
preparation. On the other hand, the carriers should dissolve in
the small intestine to release the drug for absorption. Particle
size of the suspended ASD carriers in the dosing vehicle is also
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FIGURE 4 | Images of spray-dried powders of HPMC-AS (A), Eudragit (B), and PVAP (C) dispersed in the aqueous vehicle (0.5% MC and 0.015%
Tween) up to 4h and HPMC-AS (D), Eudragit (E), and PVAP (F) in a pH6 buffer.
critical since it influences the dissolution. Hence particle size
of spray-dried powders of the three polymers dispersed in the
aqueous vehicle (0.5%MC and 0.015% Tween) up to 4 h are given
in Table 1. As shown in Figure 4, the three spray-dried polymers
formed homogenously suspended particles without aggregations
in the aqueous vehicle used (0.5% MC and 0.015% Tween) up
to 4 h, indicating most of the incorporated compounds can
probably be protected by the carriers from pre-maturely releasing
in the dosing vehicle. Table 1 shows that the mean diameters are
found to be 2.7 ± 2.9, 0.8 ± 0.5, and 0.5 ± 0.3 µm for HPMC-
AS, Eudragit, and PVAP, respectively. The 90% of particles are
below 5.0, 2.0, and 0.9µm for HPMC-AS, Eudragit, and PVAP,
respectively. As illustrated in Figure 4, they became clear solution
at pH6 (above the solubility threshold), which is the average
intestinal pH of mice and rats (McConnell et al., 2008), indicating
that the incorporated compounds can be released in the upper GI
of rodents.
The polymers tested in the present study are generally
recognized as safe in humans, and listed in the FDA’s Inactive
Ingredient Database (IID). However, as referenced earlier, while
some excipients are recognized as safe for clinical use, animal
species may respond differently (Pestel et al., 2006; Li and Zhao,
2007; Turner et al., 2011). Previously, PVAP was been evaluated
in oral toxicity studies in rats (Schoneker et al., 2003) and
subchronic dietary studies where no toxicologically meaningful
changes were noted (DeMerlis et al., 2014). Additionally, Hoshi
et al. (1985a) previously evaluated the toxicological effects of
HPMC-AS on organ function and the material was found
generally without effect although the studies did not include
an Irwin, cardiovascular, or GI transit assessment in rats.
And, while a separate study from the same authors indicate
that behavior was not affected in rats after administration
at 2.5 g/kg, it is unclear what behavioral endpoints were
measured in the study beyond mortality (Hoshi et al., 1985b)
and thus comparison to results of the present study is not
possible.
Eudragit has been tested in rats at doses up to 4800 mg/kg
without lethality (Piccinelli and de Feo, 1985). Additionally, the
safety and toxicity assessment of neutral methacrylate copolymer
has been reviewed in two publications (Eisele et al., 2011, 2013) in
support of GRAS evaluation by authors employed at Evonik who
reference a number of studies performed in rats at doses up to
2000mg/kg/d and where it is suggested that oral administration
had no adverse toxicity. However, these conclusions cannot be
easily substantiated based on several inaccessible references and
where support for lack of toxicity is based on unpublished
observations [i.e., refer to multiple citations within (Eisele et al.,
2011, 2013) by T. Hirikawa, H. Kaneto, K. Kinkel, E. Rossiello,
U. Decker, and several studies performed by F. Leuschner].
Thus, while no acute toxicity might be expected, peer-reviewed
studies related specifically to the safety of Eudragit, including
Eudragit L-100-55, on CNS, GI, and CV organ systems were not
readily available. Therefore, the effects of Eudragit and the other
polymers were systematically tested in a battery of in vivomodels
in rats commonly used in safety pharmacology assessment.
Prior to first-in-human studies, pre-clinical safety
pharmacology assays, tests, and models are positioned to
predict the clinical risk profile of NCEs. More importantly,
properly conducted safety pharmacology studies are important
given the necessity to reduce the number of late-stage failures
by way of triaging drug candidates early and allowing for
advancement of the best drug candidates based on a balance
between efficacy and safety (Morimoto et al., 2015). While
most pre-clinical in vivo safety pharmacology models employ
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TABLE 2 | Summarized observations from modified Irwin test performed at 1, 2, and 4h post-dose for PVAP, Eudragit, and HPMC-AS at 30, 100, and
300mg/kg (n = 6/group/dose) based on Irwin Score.
Category Vehicle PVAP Eudragit HPMC-AS
Stereotypy – infrequent, non-DD (chewing/grooming) – –
Excitation – infrequent, non-DD (increased motor
activity)
– –
Sedation – infrequent, non-DD (decreased motor
activity, grip reflex)
infrequent, non-DD (decreased
motor activity)
infrequent, non-DD (decreased motor activity, muscle
tone, grip reflex)
Pain – – – –
Autonomic – – – limited observations, DD (diarrhea)
Reflex – – – –
Body Temperature – – – –
Paralysis/Death – – – –
Lack of effect is denoted by a (–) in the table. Effects, when noted for specific endpoints, are listed in the table and categorized as either (1) observed infrequently, (2) observed in a
limited number of animals, or (3) were consistently observed. DD indicates dose-dependency, Non-DD indicates an observation was not dose-dependent.
quantitative and objective measurements of organ function
(e.g., blood pressure in telemetry-instrumented rodents), CNS
functional profiling is more difficult to quantify as assessments
are typically performed with the use of behavioral models that are
largely, albeit not exclusively, dependent on multiple subjective
endpoints. Indeed, classical methods to evaluate CNS functional
effects consist of observing, and scoring, behavioral responses.
The Irwin (1968) and the functional observational battery
(Moser et al., 1995) are the most commonly used assays in CNS
safety assessment that meet ICHS7A guidelines for pre-clinical
assessment of NCEs prior to testing in man (USDHHS, 2001).
In the present study that used a Modified Irwin model, when
the enteric polymers were evaluated at 1, 2, and 4-h post-dose
and relative to the control group, none elicited any marked
or consistently dose-dependent effects on any of the broad
categories of CNS function including stereotypies, excitation,
sedation, pain/anesthesia, autonomic balance, and reflexes
(Summarized in Table 2). While some qualitative observations
were recorded, none appeared related to administration of
the enteric polymers and were not qualitatively different than
animals that received the control vehicle. Additionally, while
diarrhea was observed in the HPMC-AS studies at the two later
timepoints (2 and 4-h p.a.), the effect was observed in only a
limited number of animals and was not observed in subsequent
studies designed to specifically address effects on GI functional
endpoints (gastric emptying and gastrointestinal transit time).
Thus, results from CNS safety studies using a modified Irwin
protocol demonstrate no untoward effect of the three enteric
polymers on CNS function when tested at high doses, up to
300mg/kg, and demonstrate that all three are suitable for testing
novel NCEs during pre-clinical safety evaluation. Moreover,
these results appear consistent with a separate study investigating
the pharmacological effects of HPMC-AS whereby Hoshi et al.
(1985a) demonstrated no effect on generalized behavior in
beagles and no effect on hexobarbital-induced sleeping time
(125–150mg/kg, p.o.) or motor coordination (250mg/kg, p.o.)
in rats.
Historically, drug attrition due to GI-related adverse effects
has been small although reports of this nature have increased over
the last few years and tend to be quite diverse, usually functional
FIGURE 5 | Effect of PVAP, Eudragit, and HPMC-AS enteric polymers
on GI Function in Conscious Rats. Gastric emptying (top) is shown as
weight before and after removal of stomach contents (predominately BaSO4
test meal) at 3 doses of each polymer (30, 100, or 300mg/kg; n = 7–8/group)
in comparison to the control vehicle (MC/Tween) as shown in the 0mg/kg bar.
The extent of BaSO4 traverse through the small intestine, indicative of
intestinal transit (bottom), is shown as a percent of the total intestine length.
The mean range of historical control values for both parameters is shown in
dashed lines on the y-axis.
in nature, and not limited to a single mechanism or therapeutic
area (Al-Saffar et al., 2015). Pre-clinical models have been
established to screen NCEs for effects on GI function including
gastric absorption, secretion, and emptying, gastrointestinal
motility, as well as nausea and emesis liabilities (Al-Saffar et al.,
2015). Drug-induced effects on GI function can be assessed
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as endpoints integrated into toxicology studies (Redfern, 2015)
or, as in the present study, in stand-alone safety pharmacology
studies. In the present investigation, studies were performed
using a barium sulfate test meal to assess effects on gastric
emptying and GI transit time. The extent of gastric emptying and
GI transit time was highly consistent in animals that received
the control vehicle in each of the polymer studies. Moreover,
no effects on either gastric emptying or GI transit time were
observed for any enteric polymer tested at any dose level up to
300mg/kg (Figure 5). Consistent with these findings, Hoshi et al.
(1985a) demonstrated no effect on contraction of the isolated
ileum of guinea pigs at doses up to 250mg/kg. In rats, the
study demonstrated no significant effect of HMPC-AS on BaSO4
transit in the small intestine, gastric secretions, and bile excretion.
Thus, these results demonstrate that the three enteric polymers
tested, HPMC-AS, PVAP, and Eudragit, are benign with regard
to direct or indirect effects on gastrointestinal function and are
suitable for formulation during pre-clinical safety screening in
drug discovery.
Hemodynamics, including blood pressure and heart rate,
represent important safety pharmacology endpoints with well-
established correlation to clinical observations in man (Authier
et al., 2015). This has been demonstrated in multiple studies
across therapeutic classes and drug mechanisms, and perhaps
is most referenced in regard to the off-target effects of the
CETP blocker, torcetrapib (Polakowski et al., 2009; Fryer et al.,
2012a; Al-Saffar et al., 2015), a molecule that was terminated
during late-stage clinical development after demonstration of
higher cardiovascular events and mortality in patents and
that was associated with small magnitude changes in systolic
pressure (4 mmHg) both clinically and pre-clinically (as reviewed
in Authier et al., 2015). Cardiovascular safety pharmacology
testing can be performed under acute or chronic dosing
conditions to probe underlying risk for effects of differential
underlying etiology (e.g., acute modulation of blood pressure
provoked by changes in vascular tone vs. chronic modulation
of blood pressure due to alterations in Na+ balance) (Fryer
et al., 2012c). Moreover, since cardiovascular liabilities can be
elicited via myriad physiological mechanisms (e.g., alterations
in autonomic balance, renal hemodynamics, fluid volume,
electrolyte concentrations, vascular tone, cardiac conduction)
and impacted by any number of receptors, proteins, kinases, and
channels, it is difficult to determine a priori what physiochemical
characteristics may trigger a cardiovascular response. Indeed, a
majority of compounds have been estimated to be abandoned
during lead optimization due to cardiovascular liabilities and
cardiovascular liabilities remain one of the most cited reason
for attrition due to safety in clinical development (Laverty et al.,
2011; Ferri et al., 2013; Roberts et al., 2014). However, establishing
early SAR around off-target cardiovascular effects has proven
an effective strategy to mitigate cardiovascular risk during lead
discovery (Kym et al., 2006; Lynch et al., 2006; Fryer et al., 2012b).
Thus, establishing a wide TI with regard to cardiovascular
safety is often considered a principal optimization point prior
to advancement of NCEs into clinical development. To the
author’s knowledge, only HMPC-AS has been investigated in
cardiovascular pharmacology studies. While the study employed
i.v. administration of the polymer (25 mg/kg) to beagles, no
acute effect on blood pressure or the ECG was observed (Hoshi
et al., 1985a). In the present investigation, in cardiovascular
studies performed in telemetry-instrumented rats, baseline mean
arterial blood pressure and heart rate values were consistent
between the vehicle control and groups receiving the enteric
polymers (Tables 3, 4). Administration of the enteric polymers
(PVAP, Eudragit, or HPMC-AS) at doses from 30 to 300mg/kg
had no effect on either acute hemodynamic values (Figure 6)
or chronic hemodynamic values represented as a 24-h mean
(Tables 3, 4). Moreover, the polymers had no effect on diurnal
fluctuations in heart rate due to light/dark cycles (Figure 6).
While some statistically-significant differences were detected vs.
the control vehicle group at discrete timepoints (measured and
shown at 10-min intervals over a 48-h continuous recording),
TABLE 3 | Twenty-four hour mean blood pressure values (mmHg) at baseline and after administration of an aqueous control vehicle or the enteric
polymers from 3 to 300mg/kg (n = 8/group/dose).
Phase Baseline Post-dose
mg/kg Control 30 100 300 Control 30 100 300
PVAP 97.4 ± 1.6 96.5 ± 1.2 95.6 ± 1.2 97.3 ± 2.2 97.0 ± 1.8 95.9 ± 1.1 93.9 ± 1.0 96.7 ± 2.0
Eudragit 96.7 ± 1.6 95.6 ± 1.1 95.4 ± 1.3 96.3 ± 2.0 97.3 ± 1.7 96.1 ± 1.1 95.2 ± 0.9 96.8 ± 1.8
HPMC-AS 96.3 ± 1.5 96.5 ± 1.1 96.7 ± 1.8 95.2 ± 2.3 96.4 ± 1.6 95.8 ± 1.0 95.6 ± 1.6 95.6 ± 2.1
TABLE 4 | Twenty-four hour mean heart rate values (beats/min) at baseline and after administration of an aqueous control vehicle or the enteric polymers
from 3 to 300 mg/kg (n = 8/group/dose).
Phase Baseline Post-dose
mg/kg Control 30 100 300 Control 30 100 300
PVAP 345 ± 5 333 ± 5 343 ± 3 340 ± 3 341 ± 5 330 ± 6 340 ± 3 341 ± 3
Eudragit 345 ± 5 332 ± 6 342 ± 3 343 ± 4 344 ± 5 333 ± 7 344 ± 3 343 ± 4
HPMC-AS 344 ± 6 334 ± 6 343 ± 4 343 ± 4 346 ± 5 336 ± 7 345 ± 4 345 ± 4
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FIGURE 6 | Effect of PVAP (A,B), Eudragit (C,D), and HPMC-AS (E,F) on cardiovascular function. Mean values are shown as change from baseline at 10-min
intervals during a 48-h continuous recording in telemetry-instrumented conscious rats. The control vehicle was dosed to all animals (n = 8/group) at −24 h; at 0 h
animals received the control vehicle or polymer at 30, 100, or 300mg/kg. Values statistically different than the control vehicle group are marked with asterisks; light
and dark cycle are also marked that corresponded to diurnal changes in the hemodynamic values.
no dose-dependency was observed nor were the number of
statistically-significant values increased in the post-dose period
(0–24 h) vs. the pre-dose baseline period (from −24 to 0 h).
Therefore, results of the present study demonstrate that the three
enteric polymers, HPMC-AS, PVAP, and Eudragit are benign
with regard to acute cardiovascular function and represent a
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suitable formulation for testing novel NCEs during pre-clinical
cardiovascular safety screening.
The importance of excipient interrogation a priori has
previously been highlighted by work of Pestel et al. (2006) who
investigated the effect of common excipients of dosing vehicles
in gastrointestinal, renal, and liver functional studies. They
note that poorly controlled studies are not uncommon where
a vehicle may be selected based only on dissolution-supporting
characteristics without the proper consideration for impact on
measured functional endpoints. The authors also highlight the
need for evidence-based information to enable the rational
selection of solubilizing agents suitable for pharmacological
testing (Pestel et al., 2006). Moreover, Li and Zhao (2007)
have noted that establishing literature precedent or databases
relating formulations to safety endpoints may provide valuable
support for early formulations in drug discovery where the
question of using excipients without causing adverse effects
is at the core of early formulation development. In line with
these recommendations, the present studies establish that PVAP,
HPMC-AS, and Eudragit are acceptable excipients for in vivo
safety pharmacology profiling.
CONCLUSION
Due to very limited bulk drug supplies in the fast-paced drug
discovery environment, it is impractical and almost unfeasible
to conduct an extensive full screening of polymers to select the
most optimal amorphous solid dispersion carriers for pre-clinical
safety pharmacology studies where careful consideration and
selection of the proper carrier is essential. To reduce development
timelines and consumption of drug substance, a more effective
alternative approach has been taken to evaluate pre-selected
polymers as amorphous solid dispersion carriers. Based on the
aforementioned properties and tolerability of specific polymers
(HPMC-AS, Eudragit, and PVAP) representing three classes, we
demonstrate that all are amenable as carriers for spray-dried
dispersions with appropriate physiochemical properties and,
importantly, none of the enteric polymers had any effect on CNS,
gastrointestinal, or cardiovascular functional parameters when
tested at high doses (up to 300 mg/kg) in rats. Results from the
present studies demonstrate the utility of these enteric polymers
as spray-dried dispersion carriers to enable the formulation of
poorly soluble compounds for pre-clinical safety pharmacology
evaluation, and to thereby enable an adequate TI for pre-
clinical safety during lead optimization in research and candidate
selection.
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